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Abstract
Background: Spontaneous Regression/Complete Resistant (SR/CR) mice are a colony of cancer-resistant mice that can 
detect and rapidly destroy malignant cells with innate cellular immunity, predominately mediated by granulocytes. Our 
previous studies suggest that several effector mechanisms, such as perforin, granzymes, or complements, may be 
involved in the killing of cancer cells. However, none of these effector mechanisms is known as critical for granulocytes. 
Additionally, it is unclear which effector mechanisms are required for the cancer killing activity of specific leukocyte 
populations and the survival of SR/CR mice against the challenges of lethal cancer cells. We hypothesized that if any of 
these effector mechanisms was required for the resistance to cancer cells, its functional knockout in SR/CR mice should 
render them sensitive to cancer challenges. This was tested by cross breeding SR/CR mice into the individual genetic 
knockout backgrounds of perforin (Prf-/-), superoxide (Cybb-/), or inducible nitric oxide (Nos2-/).
Methods: SR/CR mice were bred into individual Prf-/-, Cybb-/-, or Nos2-/- genetic backgrounds and then challenged 
with sarcoma 180 (S180). Their overall survival was compared to controls. The cancer killing efficiency of purified 
populations of macrophages and neutrophils from these immunodeficient mice was also examined.
Results: When these genetically engineered mice were challenged with cancer cells, the knockout backgrounds of Prf-
/-, Cybb-/-, or Nos2-/- did not completely abolish the SR/CR cancer resistant phenotype. However, the Nos2-/- 
background did appear to weaken the resistance. Incidentally, it was also observed that the male mice in these 
immunocompromised backgrounds tended to be less cancer-resistant than SR/CR controls.
Conclusion: Despite the previously known roles of perforin, superoxide or nitric oxide in the effector mechanisms of 
innate immune responses, these effector mechanisms were not required for cancer-resistance in SR/CR mice. The 
resistance was functional when any one of these effector mechanisms was completely absent, except some noticeably 
reduced penetrance, but not abolishment, of the phenotype in the male background in comparison to female 
background. These results also indicate that some other effector mechanism(s) of granulocytes may be involved in the 
killing of cancer cells in SR/CR mice.
Background
Spontaneous Regression/Complete Resistant (SR/CR)
mice are a mouse model that is capable of resisting lethal
challenges with a wide variety of cancers [1,2]. The resis-
tance resides primarily in innate leukocytes consisting of
granulocytes, monocytes, and natural killer cells which
migrate to the site of the tumor, recognize the cancer cells
via tight contact, and then destroy the tumor cells mainly
through cytolysis [1,2]. The cytolysis of cancer cells in
SR/CR mice was previously indicated to involve multiple
effector mechanisms [1-3], a number of which are associ-
ated with innate immunity. Specifically, perforin and
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granzymes were detected in the peritoneal fluid and in a
fraction of the rosettes following a challenge with S180, in
addition to a decrease in S180 killing by SR/CR mac-
rophages following the inhibition of reactive oxygen spe-
cies [3].
Several unanswered questions remain pertaining to the
roles that these various effector mechanisms play in the
killing of cancer cells by SR/CR leukocytes. In particular,
it is unknown what proportion of the perforin positive
cells were natural killer (NK) cells or cytotoxic T lympho-
cytes (CTL) and therefore the significance of perforin in
the primary response and its role in the NK killing activ-
ity in these mice remain unclear. Furthermore, since
inhibitors can have nonspecific effects on other enzymes
or can have incomplete inhibition, it is not completely
clear if the superoxide and nitric oxide effector mecha-
nisms are required for the SR/CR cancer resistance phe-
notype, or for the cancer killing activity of an individual
leukocyte population. In order to thoroughly evaluate
these effector mechanisms during the primary anticancer
response in a system with complete and specific inhibi-
tion, SR/CR mice were bred into genetic backgrounds
deficient in perforin, superoxide, and nitric oxide.
Perforin is a protein found in secretory vesicles of CTL
and NK cells, encoded by its gene on chromosome 10 [4].
When released at the immunologic synapse between a
leukocyte and its target, perforin polymerizes and forms
pores in the target's membranes [5]. While perforin is an
inefficient cytolytic agent by itself; it facilitates the release
of granzymes into the cytosol of the target cells and then
triggers apoptotic pathways [6]. In the perforin knockout
mice (Prf-/-), CTL and NK cells are present in normal
numbers, but are unable to lyse virus-infected or alloge-
neic fibroblasts in vitro [7]. Perforin knockout mice are
also more susceptible to viral pathogens, spontaneous B
cell lymphomas, and transplanted or inducible tumors [7-
11]. In the primary SR/CR response to cancer, it is likely
that the absence of perforin would have the greatest effect
on NK cells, since CTL's would require an initial priming
event.
Superoxide is one type of reactive oxygen species that is
produced by both macrophages and neutrophils for host
defense. At the immunologic synapse or phagosome,
superoxide is generated by NADPH oxidase. NADPH
oxidase is a multi-subunit complex that catalyzes the
reduction of molecular oxygen at the expense of NADPH
[12]. The gp91phox subunit, also known as NOX2, is an
essential membrane bound protein that helps form the
redox center of the enzyme [13-15]. If the gp91phox sub-
unit is missing or defective, NADPH oxidase is inactive
[16-18]. Mice with null alleles for gp91phox (Cybb-/-) on
the X chromosome lack phagocyte superoxide produc-
tion making them more susceptible to some bacterial and
fungal infections [16]. The absence of superoxide would
likely affect both macrophages and neutrophils in the pri-
mary SR/CR response to cancer; and with twice the
capacity for reactive oxygen species production, neutro-
phils may be affected the greatest [19].
Macrophages and neutrophils also produce nitric
oxide, a reactive nitrogen species that is somewhat com-
plementary to superoxide [20]. At the immunologic syn-
apse or phagosome, nitric oxide is generated by inducible
nitric oxide synthase (Nos2) which converts arginine to
citruline and nitric oxide, using molecular oxygen and
NADPH [21,22]. Mice with null Nos2 alleles on chromo-
some 11 (Nos2-/-) have virtually no serum nitric oxide
response to lipopolysaccharide (LPS) [23] and have an
altered response to many infections [24] and impaired
wound healing [25]. Since Nos2 inhibitors were previ-
ously shown not to have an effect on macrophage killing
in vitro [3], it is likely that the absence of nitric oxide will
only affect neutrophil killing activity during the primary
SR/CR response to cancer in vivo.
Here, we report the findings of the SR/CR mice bred
into the knockout backgrounds of Prf-/-, Cybb-/-, and
Nos2-/- as it relates to the survival against a primary
challenge with S180, and the evaluation of the cancer kill-
ing activity of individual leukocyte populations from
these mice.
Methods
Cell Lines and Mouse Strains
The S180 cell line was obtained from the ATCC (Manas-
sas, VA). S180 cells were either propagated in DMEM
with 10% FBS at 37°C in 5% carbon dioxide or maintained
by serial passages through wild-type (WT) C57BL/6 mice
as cancerous ascites. WT C57BL/6J mice, C57BL/6-
RAG1tm1Mom  mice, B6.129S6-Cybbtm1Din/J, B6.129P2-
Nos2tm1Lau/J, and C57BL/6-Prf1tm1Sdz/J mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME).
SR/CR mice in the C57BL/6 congenic background were
bred at the ARP facility of WFU [1]. Animals were
housed under 12-hour light/dark cycles and received a
standard laboratory chow diet. All protocols and proce-
dures were approved by the IACUC of the WFU Health
Sciences.
Prf Breeding and Screening
SR/CR C57BL/6 mice were bred with WT Prf-/- mice. At
six weeks of age, the first filial generation (F1) progeny
were screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at
ten weeks. Survivors were considered resistant, or F1 SR/
CR Prf+/- mice, and used to breed the backcross (BC or
F2) generation. F1 SR/CR Prf+/- were bred with WT Prf-/-
mice. All of the BC progeny were Prf PCR genotyped at 3-
4 weeks of age. At 6 weeks of age, the BC progeny were
screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten
weeks. The second challenge of 5 × 10e6 was instituted asSanders et al. BMC Cancer 2010, 10:121
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a safeguard against occasional failed first injections. All
WT control mice were succumbed to the challenges via
cancerous ascites. Healthy survivors were considered
resistant, or BC SR/CR mice.
Prf PCR
Tail snips were digested in DirectPCR Lysis Reagent-Tail
(Viagen), with 0.4 mg/mL proteinase K. One uL of the
lysate was used for each PCR reaction. Prf PCR genotyp-
ing was performed according to The Jackson Laboratory
standard procedures by simultaneous amplification of the
WT (Prf+) and knockout (Prf-) alleles using three primers:
oIMR1100, 5'-GCTATCAGGACATAGCGTTGG-3';
oIMR3108, 5'-GGAGGCTCTGAGACAGGCTA-3'; and
oIMR3109, 5'-TACCACCAAATGGGCCAAG-3'. The
PCR yielded products of sizes 187 bp Prf+ and 250 bp Prf-
, which were analyzed on 2% agarose gels.
Cybb Breeding and Screening
SR/CR C57BL/6 female mice were bred with WT CybbY/-
male mice. At six weeks of age, the F1 progeny were
screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten
weeks. Male survivors were designated F1 SR/CR CybbY/
+. SR/CR female survivors were designated F1 SR/CR
Cybb+/-, and used to breed the BC generation. F1 SR/CR
female Cybb+/- were bred with WT CybbY/- male mice. All
o f  t h e  B C  p r o g e n y  w e r e  C y b b  P C R  g e n o t y p e d  a t  3 - 4
weeks of age. At 6 weeks of age, the BC progeny were
screened with 1 × 10e6 S180 i.p., then 5 × 10e6 at ten
weeks. Survivors were considered resistant, or BC SR/CR
mice.
Cybb PCR
Tail snips were digested in DirectPCR Lysis Reagent-Tail
(Viagen), with 0.4 mg/mL proteinase K. 1 uL of the lysate
was used for each PCR reaction. Cybb PCR genotyping
was performed according to The Jackson Laboratory
standard procedures by simultaneous amplification of the
WT (Cybb+) and knockout (Cybb-) alleles using three
primers: oIMR0517, 5'-AAGAGAAACTCCTCTGCT-
GTGAA-3'; oIMR0518, 5'-CGCACTGGAACCCCT-
GAGAAAGG-3'; and oIMR0519, 5'-GTTCTAATTCCA
TCAGAAGCTTATCG-3'. The PCR yielded products of
sizes 240 bp Cybb+ and 195 bp Cybb-, which were ana-
lyzed on 2% agarose gels.
Histology
When showing signs of expected illness, the mice were
sacrificed. Their tissues were fixed in 10% neutral buff-
ered formalin, and subsequently embedded in paraffin.
Sections were stained with hematoxylin and eosin and
then examined.
Nos2 Breeding and Screening
SR/CR C57BL/6 mice were bred with WT Nos2-/- mice.
At six weeks of age, the F1 progeny were screened with 1
× 10e6 S180 i.p., then 5 × 10e6 at ten weeks. Survivors
were considered resistant, or F1 SR/CR Nos2+/- mice, and
used to breed the BC generation. F1 SR/CR Nos2+/- were
bred with WT Nos2-/- mice. All of the BC progeny were
Nos2 PCR genotyped at 3-4 weeks of age. At six weeks of
age, the BC progeny were screened with 1 × 10e6 S180
i.p., then 5 × 10e6 at ten weeks. Survivors were consid-
ered resistant, or BC SR/CR mice.
Nos2 PCR
DNA was isolated from tail snips using the Wizard
Genomic DNA Purification Kit (Promega, A1120). Nos2
PCR genotyping was performed according to The Jack-
son Laboratory standard procedures by simultaneous
amplification of the WT (Nos2+) and knockout (Nos2-)
alleles using three primers: oIMR1216, 5'-ACATGCA-
GAATGAGTACCGG-3'; oIMR1217, 5'-TCAACATCTC-
CTGGTGGAAC-3'; and oIMR1218, 5'-
AATATGCGAAGTGGACCTCG-3'. The PCR yielded
products of sizes 108 bp Nos2+ and 270 bp Nos2-, which
were analyzed on 2% agarose gels.
Macrophage Isolation
Four days after a 2 mL i.p. injection with 2% thioglycolate
(Sigma, B2551), macrophages were harvested by perito-
neal lavage. The cells were cultured on tissue culture
dishes for 1.5 hours in media (DMEM with 10% FBS) at
37°C. Non-adherent cells were removed by two rinses
with phosphate buffered saline (PBS) containing calcium,
and discarded. The adherent cells were incubated for 1
hour in 5 mM EDTA (in DMEM with 10% FBS) at 37°C.
The macrophages were vigorously washed off using PBS
without calcium, counted by Trypan Blue exclusion, and
resuspended at the appropriate concentrations. Purity
was > 95% macrophages as determined by hematoxylin
staining and the unique morphology of macrophages.
Neutrophil Isolation
Eighteen hours after a 2 mL i.p. injection of 2% thioglyco-
late, neutrophils were harvested by peritoneal lavage. The
cells were cultured for 1 hour in media (DMEM with 10%
FBS) at 37°C. Non-adherent cells were collected by sev-
eral light rinses with PBS containing calcium, counted by
Trypan Blue exclusion, and resuspended at the appropri-
ate concentrations. Purity was > 85% neutrophils as
determined by hematoxylin staining and typical polymor-
phic nuclei.
Griess Assay
In a 96-well plate, 2 × 10e5 macrophages or 4 × 10e5 neu-
trophils were plated in DMEM with 10% FBS, at a final
volume of 200 uL. Ten ug/mL stocks of interferon-
gamma (IFNγ; Sigma, I4777) and lipopolysaccaride (LPS;
E. Coli Serotype 0111:B4, Fluka, 62325) were freshly
mixed in a 1:1 ratio. Four uL of the mixture was added to
each stimulated well, while nothing was added to theSanders et al. BMC Cancer 2010, 10:121
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unstimulated controls. The cells were incubated at 37°C
for 24 hours. The following day, 50 uL of the media from
each well was transferred to a flat-bottomed 96-well
plate. In duplicate, a standard curve was also made with
sodium nitrite in media (124-1.9 uM, and media alone;
Sigma, S-2252) with a final volume of 50 uL per well. Fifty
uL of Griess reagent (Fluka, 03553) was added to each
well, and gently mixed. Large bubbles were popped with a
heated needle. After 15 minutes at room temperature, the
absorbance at 540 nm was read in a plate reader. The
nitrite production for each sample was calculated (aver-
age stimulated - average unstimulated nitrite produc-
tion), using the standard curve.
Adoptive Transfers
RAG1-/- recipients were given 8-10 × 10e6 macrophages
or neutrophils i.p. The following day, the recipients were
challenged with 1 × 10e4 S180 i.p. and their survival was
monitored. Moribund mice were euthanized and exam-
ined for the presence of tumor. Mice that were healthy
and ascites free, 6 weeks post injection, were considered
resistant.
Statistical Analysis
Statistical analysis was performed by the two-tailed Stu-
dent's t-test. P-values less than 0.05 were regarded as sta-
tistically significant.
Results and Discussion
Prf Breeding and Screening
SR/CR Prf+/+ mice were bred with WT Prf-/- mice. All F1
p r o g e n y  w e r e  e x p e c t e d  t o  b e  P r f +/-. When challenged
with S180, 30% of the progeny survived (Figure 1). This
was similar to the survival seen in SR/CR Prf+/+ mice [1]
which suggested that the single null allele did not have a
major effect on the SR/CR phenotype. The surviving SR/
CR F1 Prf+/- mice were fertile and were used to breed the
BC generation.
SR/CR F1 Prf+/- mice were crossed with WT Prf-/- mice.
As expected, about half of the BC progeny born were
Prf+/- and half were Prf-/- (Figure 1), indicating that perfo-
rin knockout was not embryonic lethal. When challenged
with S180, 36% of the progeny survived, which was simi-
lar to the survival rate in the SR/CR F1 Prf+/- mice. How-
ever, there was a significant survival bias in the BC
generation in which the females were twice as likely to be
resistant than the males (p = 0.012). This was unexpected
because there was no gender bias observed in the F1 gen-
eration, and neither the SR/CR mutation nor perforin
have been associated with the sex chromosomes. In con-
trast, there was no significant difference in overall sur-
vival between the Prf+/- and Prf-/- mice, indicating that
perforin was not required for the initial SR/CR pheno-
type in vivo.
Cybb Breeding and Screening
One noticeable thing was that the purchased breeders
with Cybb-KO were created in a mixed genetic back-
ground of C57BL/6 and 129. Nevertheless, the potential
impact of a mixed genetic background between C57BL/6
and 129 is currently unknown. SR/CR female Cybb+/+
mice were crossed with WT male CybbY/-  mice. The
males were expected to be normal, or CybbY/+, and the
females were expected to be Cybb +/-. When challenged
with S180, 29% of the progeny survived (Figure 2), which
was similar to the rate seen in SR/CR with normal
NADPH oxidase genes [1]. Again, there was a significant
female survival bias (p = 0.008). Even though the males
should have normal NADPH oxidase activity, the F1
females were twice as likely to be resistant. Overall, the
single null allele in the females did not appear to have a
significant negative effect on the SR/CR phenotype, so
the surviving SR/CR F1 Cybb+/- mice which were fertile
were then used to breed the BC generation.
Figure 1 SR/CR Mice Do Not Require Perforin to Survive S180 
Challenges. SR/CR mice were bred into the perforin (Prf) knockout 
background. Progeny that survived two challenges with S180, remain-
ing healthy and cancer free, were considered resistant. Similar survival 
rates were seen for the BC Prf+/- and Prf-/- mice.
Prf F1 Generation
Female Male Overall
Genotype Prf (+/-) Prf (+/-)
Total Progeny 41 47 88
Total Resistant 12 14 26
Percent Resistant 29% 30% 30%
Prf BC Generation
Female Female Male Male Overall
Genotype Prf (+/-) Prf (-/-) Prf (+/-) Prf (-/-)
Total Progeny 20 20 18 25 83
Total Resistant 10 10 3 7 30
Percent Resistant 50% 50% 17% 28% 36%
Figure 2 SR/CR Mice Do Not Require Superoxide to Survive S180 
Challenges. SR/CR mice were bred into the superoxide (Cybb) knock-
out background. Progeny that survived two challenges with S180, re-
maining healthy and cancer free, were considered resistant. Similar 
survival rates were seen for the BC progeny with or without Cybb; how-
ever, there was a trend that the males were more cancer sensitive.
Cybb F1 Generation
Female Male Overall
Genotype Cybb (+/-) Cybb (Y/+)
Total Progeny 64 83 147
Total Resistant 26 17 43
Percent Resistant 41% 21% 29%
Cybb BC Generation
Female Female Male Male Overall
Genotype Cybb (+/-) Cybb (-/-) Cybb (Y/+) Cybb (Y/-)
Total Progeny 27 24 28 25 104
Total Resistant 11 5 6 5 27
Percent Resistant 41% 21% 21% 20% 26%Sanders et al. BMC Cancer 2010, 10:121
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SR/CR F1 female Cybb+/- mice were crossed with WT
male CybbY/- mice to generate the BC generation. The
choice of using female F1s as breeders was to generate all
4 possible groups: SR/Cybb-KO/males, SR/Cybb-KO/
females, WT/Cybb-KO/males and WT/Cybb-KO/
females. As a result, SR/CR groups can be compared to
WT  g r o u p s  t h a t  c a m e  f r o m  a  s a m e  b r e e d i n g  s c h e m e .
There was an even distribution of mice born by gender
and expected Cybb genotypes (Figure 2), indicating that
there was no embryonic lethality. When challenged with
S180, 26% of the progeny survived, which was similar to
the survival rate seen in the F1 mice. There were no sig-
nificant differences in survival by either gender or geno-
type; but there was a general trend that female Cybb+/-
mice had a higher frequency of resistance than the other
groups. Since there were resistant Cybb-/- females and
CybbY/- males, superoxide did not appear to be required
for the initial SR/CR phenotype in vivo.
Cybb Histology
Tissues were taken from older, moribund SR/CR Cybb-/-
and CybbY/- mice to check for malignancies. Large refrac-
tile crystals were observed in the lungs of some of the
mice (Figure 3); but were not detected in the lungs of any
of the SR/CR Cybb normal or Cybb+/- mice. The majority
of the crystals were slender rods with tapered ends;
although, a few were larger rhomboids. Following hema-
toxylin and eosin staining, the crystals were eosinophilic
(light pink) and translucent. While one of the mice had a
few scattered crystals, the rest had an abundance of crys-
tals associated with inflammatory sites. Macrophages and
multinucleated macrophage giant cells were often seen
adjacent to the crystals, possibly attempting to engulf
them. The crystals were similar in appearance to Char-
cot-Leyden crystals that consist of lysophospholipase and
are associated with pulmonary inflammation [26]. They
are also similar in appearance to Ym1 crystals found in
the aging lungs and at sites of chronic inflammation in
p47phox knockout mice [27]. YM1 is a chitinase family
protein that is found in macrophages and myeloid cells
located in the spleen and bone marrow and, also, pulmo-
nary macrophages [28]. p47phox knockout mice are phe-
notypically similar to Cybb-/- mice since they both have
defective phagocyte NADPH oxidase complexes and are
consequently, superoxide deficient. Therefore, it is highly
likely that the crystals are composed of Ym1.
Nos2 Breeding and Screening
SR/CR Nos2+/+ mice were crossed with WT Nos2-/- mice,
and all F1 progeny were expected to be Nos2 +/-. When
challenged with S180, 30% of the progeny survived (Fig-
ure 4). Since this was similar to the survival rate seen in
SR/CR Nos2+/+ mice [1], the single null allele did not
appear to have a significant effect on the SR/CR pheno-
type. However, there was a significant survival bias based
on gender (p = 0.006) in which females were about twice
as likely to be resistant than males. This was unexpected
since neither the SR/CR mutation nor the Nos2 gene has
been associated with the sex chromosomes. The surviv-
ing SR/CR F1 Nos2+/- mice were fertile, and were used to
breed the BC generation.
SR/CR F1 Nos2+/- mice were crossed with WT Nos2-/-
mice to generate the BC generation. As expected, about
half the BC progeny were Nos2+/- and half were Nos2-/-
(Figure 4), indicating that there was no embryonic lethal-
ity. When challenged with S180, 31% of the progeny sur-
vived, which was similar to the survival seen in the SR/CR
F1 Nos2+/- mice. Again, there was a significant survival
bias based on gender (p = 0.002), in which females were
twice as likely to be resistant compared to males. Further-
more, there was a strong general trend that Nos2-/- mice
were less resistant than Nos2+/- mice (p = 0.078). Impor-
tantly, this is the first time in which the absence of a single
effector mechanism, namely Nos2, may have a negative
effect, but not abolishment, on the germline transmission
rate of SR/CR anticancer response in vivo.
Nitric Oxide Production
In order to confirm that nitric oxide production was
absent in SR/CR Nos2-/- macrophages and neutrophils,
the Griess assay was performed. Since nitric oxide is a
Figure 3 Lung Crystals Found in Moribund SR/CR Cybb-/- and Cyb-
bY/- Mice. Hematoxylin and eosin stained sections of lung showed the 
presence of large eosinophilic crystals (arrows) in the lungs of mori-
bund CybbY/- (B) and Cybb-/- (C) mice. No crystals were observed in the 
lungs of age-matched SR/CR Cybb+/- (A) or Cybb+/+ mice.
Figure 4 SR/CR Mice Do Not Require Nitric Oxide to Survive S180 
Challenges. SR/CR mice were bred into the inducible nitric oxide syn-
thase (Nos2) knockout background. Progeny that survived two chal-
lenges with S180, remaining healthy and cancer free, were considered 
resistant. Similar survival rates were seen for the BC Nos2+/- and Nos2-
/-; however, there was a strong trend that the males were more cancer 
sensitive.
Nos2 F1 Generation
Female Male Overall
Genotype Nos2 (+/-) Nos2 (+/-)
Total Progeny 103 127 230
Total Resistant 40 28 68
Percent Resistant 39% 22% 30%
Nos2 BC Generation
Female Female Male Male Overall
Genotype Nos2 (+/-) Nos2 (-/-) Nos2 (+/-) Nos2 (-/-)
Total Progeny 28 17 15 28 88
Total Resistant 14 7 3 3 27
Percent Resistant 50% 41% 20% 11% 31%Sanders et al. BMC Cancer 2010, 10:121
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short-lived molecule, one of its more stable by-products,
nitrite, is commonly measured. Following stimulation
with interferon gamma (IFNγ) and LPS, the nitrite pro-
duction of macrophages and neutrophils from WT
Nos2+/+, SR/CR Nos2+/+, and SR/CR Nos2-/- mice was
quantified (Figure 5). As expected, macrophages and neu-
trophils from both WT and SR/CR Nos2+/+ mice had
robust nitrite production; while SR/CR Nos2-/-  mac-
rophages and neutrophils had no detectable nitrite pro-
duction.
Adoptive Transfers
Nitric oxide is one of the known effector mechanisms
used by macrophages and neutrophils. If nitric oxide was
the chief effector mechanism used by SR/CR mac-
rophages or neutrophils to kill cancer cells, then the
absence of nitric oxide would significantly weaken or
abolish this activity. The cancer killing activity of SR/CR
Nos2-/- macrophages and neutrophils was tested by trans-
ferring purified populations of each cell type to a non-
resistant WT recipient followed by a challenge with lethal
cancer cells. To study the effect of the transferred innate
leukocytes in the absence of adaptive immunity, WT
recombination activating gene 1 (Rag1) knockout mice
were used as recipients. By using this experimental setup,
we were able to determine whether SR/CR Nos2-/- mac-
rophages and neutrophils could transfer the anticancer
phenotype as efficiently as SR/CR Nos2+/+ macrophages
and neutrophils. The same survival trend was seen in
both the macrophage and neutrophil recipients in which
the SR/CR Nos2-/- leukocytes conferred less protection
when compared to SR/CR Nos2+/+ leukocytes (Figure 6).
These results suggest that nitric oxide may be one of the
major effector mechanisms used by SR/CR macrophages
and neutrophils to kill cancer.
Conclusions
The SR/CR anticancer response was previously shown to
involve multiple leukocyte subsets that can work collec-
tively or independently [1-3]. It has also been shown that
the anticancer response of the SR/CR mice involves mul-
tiple effector mechanisms [3]. However, it was not known
if the complete abolishment of any one effector mecha-
nism would affect the SR/CR anticancer response due to
the overlapping functional roles that many of the leuko-
cyte populations displayed. Our current study shows that
the SR/CR mice were capable of surviving a primary chal-
lenge with a lethal dose of S180 even with the genetic
knockout of perforin, superoxide, or nitric oxide. In the
absence of any one of these effector mechanisms, the can-
cer cells can still be destroyed leading to survival of the
challenged mice. From these results, it is likely that only
global immunosuppression, affecting multiple leukocyte
populations and their effector mechanisms, would be
able to abolish the SR/CR phenotype.
One intriguing finding was the important role that
nitric oxide plays in the anticancer activity of the SR/CR
macrophages and neutrophils. When SR/CR Nos2-/- mac-
rophages and neutrophils were transferred into cancer-
sensitive WT mice, the SR/CR Nos2-/- cells proved to be
less protective against an S180 challenge compared to
cells from SR/CR Nos2+/+ mice. These results suggest that
nitric oxide may be one of the major effector mechanisms
used by SR/CR macrophages and neutrophils to kill can-
cer cells. However, at the same time these results also
suggest that the SR/CR macrophages and neutrophils
have additional anticancer effector mechanisms in place,
since the Nos2-/- transferred cells still provided some pro-
tection. In order to continue to evaluate the significance
Figure 5 SR/CR Nos2 Knockout Macrophages and Neutrophils 
Have No Detectable Nitric Oxide Production Following LPS and 
IFNγ Stimulation. Thioglycolate elicited macrophages and neutro-
phils were stimulated with LPS and IFNγ for 24 hours. Nitrite levels, an 
indirect measure of nitric oxide production, were assessed by the 
Griess Assay. Nitrite levels for WT (n = 5) and SR/CR (n = 5) Nos2+/+ mac-
rophages were comparable, but significant levels of nitrites were not 
detected (n.d.) in SR/CR Nos2-/- macrophages (n = 3). Nitrite levels for 
WT (n = 4) and SR/CR (n = 3) Nos2+/+ neutrophils were also compara-
ble, but significant levels of nitrites were not detected in SR/CR Nos2-/
- neutrophils (n = 3).
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of other effector mechanisms, the killing activity of mac-
rophages and neutrophils from SR/CR Nos2-/- mice will
need to be assessed in combination with inhibitors of the
other known effector mechanisms. Since the knockouts
of perforin, superoxide and nitric oxide alone did not
abolish the anticancer ability of the SR/CR mice, then the
production of SR/CR mice with multiple effector mecha-
nism knockouts may also be necessary for more complete
characterization of the SR/CR phenotype.
The gender bias that was observed among all three
knockout lines of mice was quite an unexpected finding.
In several generations, female mice displayed a signifi-
cantly higher percentage of cancer resistance among the
challenged mice. Since the SR/CR mutation, Nos2 gene,
and perforin gene are not X-linked, it is possible that
there may be an unidentified X-linked gene that may
enhance the SR/CR phenotype. However, since the gen-
der bias is not consistently observed in the SR/CR breed-
ing (data not shown), the bias may alternatively stem
from the knockout backgrounds. The influence that hor-
mone levels play may be another explanation for the dif-
ferences observed between males and females. Many
leukocyte subsets express hormone receptors [29] and in
comparison to males, females tend to have more vigorous
cellular and humoral immune reactions which are
thought to make them more resistant to certain infec-
tions and at greater risk for autoimmunity [30]. WT
males and females appear equally sensitive to S180; how-
ever, when the SR/CR phenotype is in an immunocom-
promised background, the more vigorous immune
response of the females may provide a slight survival
advantage. One more explanation for the sex bias could
reside in the fact that S180 immunostain positively for a
Y-marker antigen (unpublished results), which would
m a k e  S180  mo r e  a n t ig e nic i n a f em a le  ba c kgr ound.  In
males, this would be recognized as a self epitope, while in
females it would be recognized as a foreign epitope and,
therefore, could promote rejection of the transplanted
cancer. The presence of a Y-antigen on S180 does not
appear to matter for mice with a cancer-sensitive WT
background, since males and females equally succumb to
cancer challenge. However, when the SR/CR phenotype is
introduced into an immunocompromised background,
the extra antigenicity from the Y-antigen could provide a
slight survival advantage for female mice.
Another possibility for this sex bias could be due to a
possible weakening of the resistance strength as a result
of continuous breeding for years. For example, in the first
few generations of SR/CR mice, they could tolerate chal-
lenges of up to 10e9 S180 cells. In recent years, however,
the maximum tolerated dose (MTD) seemed to have
dropped to about 10e8 S180 cells (Cui et all, unpublished
observations). Even with such a drop in MTD, the resis-
tant phenotype of SR/CR mice is still unequivocal in
comparison to non-resistant (WT) mice that would suc-
cumb to less than 10e5 or even less than 10e4 S180 cells.
The decrease of MTD may reflect a possibility that the
genetic components in the early generations may have
multiple copies that were reduced to fewer copies or sin-
gle copy in the later generations after years of breeding. If
this is the case, the high MTD in early generations of SR/
CR mice might have overcome some subtle influences,
such as sex background. On the other hand, some subtle
influences may show up when MTD was decreased as a
result of fewer copy number for the underlying gene/
mutation. The MTD could also be further decreased, but
not abolished, by knockout of some participating but
essential pathway for effector mechanisms. This could
further exacerbate the impact of otherwise subtle influ-
ences.
Collectively these findings support the prior reports
that the SR/CR anticancer response is the result of a con-
certed effort from several leukocyte populations that uti-
lize multiple effector mechanisms. The many overlapping
processes enable the host to achieve the same end result,
elimination the cancer cells and survival. These findings
also demonstrate that a highly effective anticancer
response can be mediated by innate cellular immunity
that requires no additional manipulation, supporting the
idea that leukocytes of innate immunity could potentially
be used as therapeutic agents to prevent or even to treat
cancers.
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